ArticleCureus2025
Use of Partial Splenic Embolization Following a Transjugular Intrahepatic Portosystemic Shunt to Reduce Persistent Portal Hypertension Sequelae.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transjugular intrahepatic portosystemic shunt (TIPS) placement is a well-established intervention for portal hypertension. However, some patients experience persistent complications such as encephalopathy, ascites, or thrombocytopenia, especially when further TIPS optimization is not technically possible. Partial splenic embolization (PSE), typically performed for hypersplenism or certain hematologic conditions, can reduce portal venous inflow and improve cytopenias; however, its use as an adjunct to TIPS is less well described. We present the case of a 73-year-old male with cirrhosis secondary to hepatitis C who developed recurrent ascites, worsening encephalopathy, and refractory thrombocytopenia following portal vein recanalization with TIPS placement 18 months prior. The patient's TIPS could not be further optimized due to technical limitations. Imaging demonstrated marked splenomegaly and an enlarged splenic artery, suggesting increased splenic contribution to portal inflow. PSE of the lower pole was performed. Post-procedure, the patient experienced significant clinical improvement. Encephalopathy episodes resolved, no ascites was seen on follow-up CT, and platelet count rose from <50,000/µL to >100,000//µL. The patient subsequently developed a splenic abscess requiring percutaneous intervention. PSE may serve as an effective adjuvant to TIPS in selected patients with persistent portal hypertension and cytopenias when further TIPS optimization is not possible. This case highlights the potential for PSE to reduce portal inflow and improve platelet count, suggesting an expanded role in the management of complex portal hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.